KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to -$6.6 billion.

  • Vertex Pharmaceuticals' Enterprise Value fell 804.79% to -$6.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.6 billion, marking a year-over-year decrease of 804.79%. This contributed to the annual value of -$6.6 billion for FY2025, which is 804.79% down from last year.
  • Vertex Pharmaceuticals' Enterprise Value amounted to -$6.6 billion in Q4 2025, which was down 804.79% from -$6.3 billion recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Enterprise Value registered a high of -$5.8 billion during Q2 2024, and its lowest value of -$11.9 billion during Q3 2023.
  • For the 5-year period, Vertex Pharmaceuticals' Enterprise Value averaged around -$8.3 billion, with its median value being -$7.2 billion (2021).
  • In the last 5 years, Vertex Pharmaceuticals' Enterprise Value tumbled by 6523.35% in 2021 and then surged by 4842.16% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Enterprise Value (Quarter) stood at -$7.5 billion in 2021, then tumbled by 43.24% to -$10.8 billion in 2022, then dropped by 4.08% to -$11.2 billion in 2023, then soared by 45.48% to -$6.1 billion in 2024, then fell by 8.05% to -$6.6 billion in 2025.
  • Its last three reported values are -$6.6 billion in Q4 2025, -$6.3 billion for Q3 2025, and -$6.4 billion during Q2 2025.